Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study.

Trial Profile

Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Eicosapentaenoic acid (Primary) ; Pitavastatin (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Hyperlipidaemia
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms CHERRY
  • Most Recent Events

    • 17 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2015 According to an Amarin Corporation media release, abstract of trial was published in Circulation.
    • 09 Nov 2015 According to an Amarin Corporation media release, results from this trial were presented at the American Heart Association Scientific Sessions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top